Janux Therapeutics, Inc. — Q3 2021 Form 10-Q
Reporting period: Three and nine months ended September 30, 2021. Filed November 9, 2021. Janux is a preclinical-stage biopharmaceutical company developing cancer immunotherapies; it has no approved products and has not generated product sales.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Collaboration revenue | $1.2 million | None | $2.0 million | None |
| Research and development expense | $8.4 million | $0.8 million | $15.1 million | $2.1 million |
| General and administrative expense | $3.7 million | $0.4 million | $6.4 million | $1.1 million |
| Total operating expenses | $12.1 million | $1.3 million | $21.5 million | $3.2 million |
| Net loss | $10.8 million | $1.3 million | $19.3 million | $5.1 million |
| Operating cash used | — | — | $6.5 million | $2.7 million |
At September 30, 2021, cash and cash equivalents were $39.4 million and short-term investments were $348.1 million, totaling $387.5 million. Current assets were $389.6 million; total assets were $391.1 million. Total liabilities were $14.3 million, including $7.1 million of deferred revenue. The filing reports no outstanding borrowings at period-end. Product gross margins are not applicable because Janux has no product sales.
For the first nine months, investing cash outflow was $348.3 million, primarily reflecting purchases of short-term investments net of maturities; financing cash inflow was $386.4 million, chiefly from the IPO and preferred-stock offerings. These investment purchases shifted cash into short-term investments and are not equivalent to operating cash burn.
Changes versus prior comparable periods
- Revenue began in 2021 under the Merck collaboration; all reported revenue relates to one customer. Merck revenue was $1.2 million in Q3 and $2.0 million for the nine-month period. Deferred revenue under the agreement was $7.1 million at quarter-end, of which $5.3 million was current.
- Year-to-date net loss increased by $14.1 million from 2020, while operating expenses rose by $18.3 million, reflecting expanded research and development, personnel and facilities, stock-based compensation, and public-company costs. 2021 results also included $0.2 million of interest income; 2020 included $1.9 million of note-related interest and fair-value expense.
- Janux raised $180.5 million net from Series A and B preferred-stock sales and $204.1 million net from its June IPO. Preferred shares converted into common stock at the IPO; stockholders’ equity was $376.8 million at September 30, compared with a deficit of $14.6 million at December 31, 2020.
Outlook, commentary, and risks
- Management expects substantial operating losses for the next several years and says existing cash, cash equivalents and investments should fund operations for at least 12 months following the filing. Janux expects to need additional capital to complete development and commercialization; financing may dilute shareholders or require granting rights to programs or technology.
- All programs were in preclinical or discovery stages. Management expected to submit an IND for PSMA-TRACTr in the first half of 2022, EGFR-TRACTr in the second half of 2022, and TROP2-TRACTr in 2023, and expected to select a PD-L1xCD28 TRACIr development candidate in 2022. These are forward-looking plans, not financial guidance.
- Management cited non-human-primate data as supporting the potential for reduced cytokine-release and healthy-tissue toxicity and improved dosing intervals, while emphasizing that human safety and efficacy remain unproven. The company highlights clinical-development, regulatory, manufacturing, third-party, intellectual-property, financing, competition and COVID-19 risks.
- In October 2021, after quarter-end, Janux signed a 126-month office and laboratory lease expected to commence in July 2022. Base rent is approximately $38.0 million, with up to $10.6 million of landlord improvement allowance; the company also arranged a $0.8 million letter of credit. This is a significant future commitment, subject to lease terms and allowances.
- The filing reports no material legal proceedings. A WuXi cell-line license carries potential low-single-digit royalties on specified net sales if products are manufactured by a third party, with buyout options. Management reported effective disclosure controls; it had not yet been required to assess internal control over financial reporting.
Important facts for investors to verify
- Progress against the stated IND and candidate-selection timelines, and whether preclinical findings translate into human safety and efficacy.
- Cash runway assumptions, future R&D spending and the timing and terms of any additional financing.
- Merck collaboration scope, remaining research obligations, potential target selection, milestones and the concentration of revenue in one customer.
- Lease commencement, construction and allowance terms, total occupancy costs, and the related letter-of-credit conditions.
- Share-count and dilution disclosures: the September 30 balance sheet shows 41,171,963 common shares outstanding and 41,611,510 issued, while the cover reports 41,611,510 outstanding as of November 5, 2021. Investors should confirm the reconciliation and subsequent share changes.